D-Vine50 ml

D-Vine is a concentrated oral liquid formulation of vitamin D3 (cholecalciferol) used for the following indications:

Established / FDA-recognized uses

• Prevention of vitamin D deficiency in individuals with inadequate dietary intake, limited sun exposure, malabsorption syndromes, or increased requirements (e.g. exclusively breastfed infants, older adults, individuals with darker skin, obesity, or those on long-term anticonvulsant or corticosteroid therapy).
• Treatment of diagnosed vitamin D deficiency (low serum 25-hydroxyvitamin D), used at higher, physician-directed doses until levels normalize, followed by maintenance dosing.

Guideline-supported adjunct uses

• Adjunct in the management of osteoporosis, given together with adequate calcium intake, to support bone mineralization and reduce fracture risk in at-risk populations.
• Adjunct therapy in hypoparathyroidism and certain conditions of impaired calcium/vitamin D metabolism, under specialist supervision.

D-Vine is not a substitute for calcium supplementation, weight-bearing exercise, or other components of a comprehensive bone-health or deficiency-correction plan, and should be used only on medical advice for indications beyond routine dietary supplementation.

Each mL of Colecalciferol USP 2000 IU/ml oral solution contains Cholecalciferol (Vitamin D3) USP equivalent to 2000 IU (50 micrograms), in an oil-based or water-dispersible liquid vehicle suitable for drop-wise oral administration.

D-Vine is a fat-soluble vitamin preparation containing cholecalciferol (vitamin D3), the naturally occurring form of vitamin D synthesized in human skin on exposure to ultraviolet light and obtained from certain dietary sources. It is formulated as a concentrated oral liquid (drops) providing 2000 IU of vitamin D3 per mL, allowing flexible, accurately titratable dosing.

Vitamin D plays a central role in calcium and phosphate homeostasis, bone mineralization, and neuromuscular function. D-Vine is used to prevent and correct vitamin D deficiency and to support bone health as part of a broader treatment plan.

D-Vine belongs to the therapeutic class of Vitamin D and its analogues, specifically fat-soluble vitamin supplements used in the prevention and treatment of vitamin D deficiency and metabolic bone disorders.

Colecalciferol USP 2000 IU/ml supplies cholecalciferol, which is biologically inactive until metabolized. It undergoes hydroxylation in the liver to 25-hydroxyvitamin D (calcidiol), the major circulating and storage form, and subsequently in the kidney to 1,25-dihydroxyvitamin D (calcitriol), the biologically active hormone.

Active vitamin D increases intestinal absorption of calcium and phosphate, promotes renal tubular reabsorption of calcium, and works with parathyroid hormone to regulate serum calcium and support normal bone mineralization and remodeling. It also has effects on neuromuscular function, immune modulation, and cell differentiation.

After oral administration, cholecalciferol from Colecalciferol USP 2000 IU/ml is absorbed in the small intestine (absorption is enhanced by dietary fat) and stored in adipose tissue and muscle, giving it a long biological half-life measured in weeks.

D-Vine is for oral use only. Always use the accompanying dropper or measuring device to withdraw and administer the exact prescribed volume. Store the dropper clean and dry between uses. Do not administer directly from an un-calibrated spoon.

Clinically significant interactions with D-Vine include:

• Thiazide diuretics: Concurrent use may increase the risk of hypercalcemia by reducing renal calcium excretion; calcium levels should be monitored.
• Corticosteroids: May reduce vitamin D absorption and impair its effect on calcium metabolism, potentially requiring dose adjustment.
• Cholestyramine, colestipol, orlistat, and mineral oil: May reduce intestinal absorption of vitamin D; separate dosing times where possible.
• Phenytoin and phenobarbital: May accelerate hepatic metabolism of vitamin D, reducing its effectiveness.
• Digoxin: Hypercalcemia resulting from excessive vitamin D intake increases the risk of digoxin toxicity and cardiac arrhythmia; caution is advised in patients on digoxin.
• Magnesium-containing antacids: In patients with chronic kidney disease, concurrent use with vitamin D may risk hypermagnesemia.

Inform the prescriber of all other vitamin D-containing supplements, multivitamins, or calcium products being used to avoid inadvertent excessive total intake.

At recommended doses, D-Vine is generally well tolerated and adverse effects are uncommon. Side effects are primarily associated with excessive intake leading to hypercalcemia (see Overdose and Precautions), and may include:

• Nausea, vomiting, constipation, or decreased appetite
• Weakness, fatigue, or headache
• Increased thirst and urination
• Rarely, allergic reactions such as rash or itching

D-Vine should be used in pregnancy and lactation only at doses that do not exceed the recommended dietary allowance unless a physician has specifically diagnosed deficiency and prescribed a higher, monitored dose. Use only if clearly needed, and only under medical supervision, as excessive vitamin D intake during pregnancy has been associated with risk to the fetus (including hypercalcemia). Cholecalciferol is excreted in breast milk; breastfeeding mothers should follow the physician's recommended dose and not exceed it. Consult a physician before use during pregnancy or breastfeeding.

The following precautions apply to the use of D-Vine:

• Renal impairment: Calcium and vitamin D handling is altered in renal disease; use D-Vine under close medical guidance, as dose adjustment and monitoring may be needed.
• Avoid excessive total intake: Do not exceed the recommended daily vitamin D intake from all combined dietary and supplement sources; cumulative excess intake can cause hypercalcemia (see Side Effects and Overdose).
• Concurrent thiazide diuretic use: Increases the risk of hypercalcemia (see Interactions).
• Accurate liquid dosing is essential: Because of the concentrated potency of this formulation, always measure doses with the provided dropper or measuring device to avoid inadvertent overdose. This is particularly important in infants and young children, in whom dosing errors with concentrated liquid vitamin D formulations are a recognized safety concern.
• Monitoring: Periodic monitoring of serum vitamin D and calcium levels may be reasonable with higher-dose or prolonged supplementation, per clinical judgment.
• Sarcoidosis, hyperparathyroidism, or other granulomatous disease: Use with caution, as these conditions increase sensitivity to vitamin D and risk of hypercalcemia.

Overdose of D-Vine can cause vitamin D toxicity and hypercalcemia, with symptoms such as persistent nausea and vomiting, constipation, weakness, confusion, excessive thirst, frequent urination, and in severe or prolonged cases, kidney damage or abnormal heart rhythm.

If overdose is suspected, discontinue the product immediately and seek immediate medical attention or contact a poison control center/emergency services. Do not attempt to manage a suspected overdose at home; treatment requires medical evaluation and may involve fluids and other supportive measures under professional care.

Store at room temperature (below 30°C), away from light and moisture. Do not freeze. Keep the bottle tightly closed and out of reach of children.

• Pediatric use: D-Vine may be used in infants and children for prevention and treatment of vitamin D deficiency at weight- and age-appropriate doses (see Dosage and Administration). Extra care is needed to measure the exact volume using the provided dropper, given documented cases of dosing errors with concentrated liquid vitamin D products in this age group.
• Elderly: Generally safe at recommended doses; elderly patients may have reduced cutaneous vitamin D synthesis and benefit from supplementation, but renal function and calcium levels should be considered.
• Renal impairment: Use under close medical supervision with monitoring, as impaired renal activation and clearance of vitamin D metabolites can predispose to abnormal calcium handling (see Precautions).
• Hepatic impairment: Impaired hepatic hydroxylation may reduce conversion to active metabolites; dose adjustment or use of an active vitamin D analogue may be considered by the physician.

Duration of treatment with D-Vine depends on the indication. Deficiency-correction regimens are typically continued for 8–12 weeks, after which vitamin D status is reassessed and therapy is transitioned to a lower maintenance dose. For prevention or adjunct bone-health use, maintenance dosing may continue long-term under periodic medical review. Do not continue high-dose treatment beyond the prescribed course without physician reassessment.

Fat-soluble vitamins; Vitamin D and analogues

Colecalciferol USP 2000 IU/ml provides cholecalciferol (vitamin D3), which is sequentially hydroxylated in the liver to calcidiol (25-hydroxyvitamin D) and then in the kidney to calcitriol (1,25-dihydroxyvitamin D), the active hormonal form. Calcitriol binds vitamin D receptors in the intestine, bone, kidney, and parathyroid gland to increase intestinal calcium and phosphate absorption, regulate renal calcium reabsorption, and support normal bone mineralization in coordination with parathyroid hormone.

D-Vine is used in infants and children for the prevention and treatment of vitamin D deficiency, including in exclusively breastfed infants who are at higher risk of inadequate vitamin D intake. Dosing is weight- and age-based and should follow pediatrician guidance (see Dosage and Administration). Because this is a concentrated liquid formulation, caregivers must use the supplied calibrated dropper for every dose; inaccurate measurement (e.g. using household spoons) can lead to underdosing or, more concerningly, toxic overdosing, which has been a recognized safety issue with concentrated liquid vitamin D products in infants. Safety and efficacy of doses above those recommended for age have not been established, and any dose escalation should occur only under physician supervision.